Literature DB >> 7810941

Host-directed and immune-based therapies for human immunodeficiency virus infection.

M M Lederman1.   

Abstract

This essay reviews the rationale underlying host-directed or immune-based therapeutic strategies for human immunodeficiency virus (HIV) infection and its complications. These approaches have seen only limited trial in the past 10 years, but as more is learned about the immunopathogenesis of HIV disease and as the limitations of virus-directed therapies become more apparent, the need to pursue other therapeutic avenues has become increasingly important. Moreover, properly designed trials of host-directed and immune-based therapies can provide key insights into the pathogenesis of HIV disease that may be otherwise unattainable through in vitro studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7810941     DOI: 10.7326/0003-4819-122-3-199502010-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

1.  CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.

Authors:  Jean-Michel Escola; Gabriel Kuenzi; Hubert Gaertner; Michelangelo Foti; Oliver Hartley
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

2.  Virus interactions with human signal transduction pathways.

Authors:  Zhongming Zhao; Junfeng Xia; Oznur Tastan; Irtisha Singh; Meghana Kshirsagar; Jaime Carbonell; Judith Klein-Seetharaman
Journal:  Int J Comput Biol Drug Des       Date:  2011-02-17

3.  A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study.

Authors:  Mike Youle; Sean Emery; Martin Fisher; Mark Nelson; Lisa Fosdick; George Janossy; Clive Loveday; Ann Sullivan; Christian Herzmann; Handan Wand; Richard T Davey; Margaret A Johnson; Jorge A Tavel; H Clifford Lane
Journal:  PLoS Clin Trials       Date:  2006-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.